Clark, G.J. et al. (2009) Trends Immunol. 30:209. Sui, L. et al. (2004) Biochem. Biophys. Res. Commun. 319:920. Alvarez-Errico, D. et al. (2004) Eur. J. Immunol. 34:3690. Korver, W. et al. (2009) Leukemia 23:1587.
LMIR3, also known as CD300f, CD300LF, IREM-1, CLM-1, IgSF13, DIgR1, and MAIR-V, is a 50-60 kDa glycoprotein member of the immunoglobulin superfamily. Human LMIR3 consists of a 137 amino acid (aa) extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane segment, and a 113 aa cytoplasmic domain that contains multiple immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or ITIM-like sequences. Within the ECD, human LMIR3 shares 43% aa sequence identity with mouse and rat LMIR3. LMIR3 is expressed on the surface of dendritic cells, monocytes, granulocytes, and mast cells as well as on acute myeloid leukemia (AML) blasts. LMIR3 is up-regulated on monocytes surrounding experimentally-induced spinal cord demyelination and functions as a negative regulator of inflammation in the CNS.
2μg (R: reducing condition, N: non-reducing condition).